A Phase 4 interventional study of Dutasteride/Tamsulosin in Prostatic Hyperplasia, sponsored by GlaxoSmithKline. Terminated at 1 site in Vietnam. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-08-20.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing dutasteride in Prostatic Hyperplasia — 1 open to participants now, 1 under way, none of them phase 3. Dutasteride · Prostatic Hyperplasia.
Among the 27 studies testing dutasteride in Prostatic Hyperplasia, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 10 in phase 4, and was the 21st registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →1 of the 27 studies testing dutasteride in Prostatic Hyperplasia is open now, in 1 country. Recruiting first, the newest first:
Mohamed Mahmoud Dogha · Sites in Egypt
Ages 50+ · Men only
By country, each count listing its studies:
Dutasteride: first FDA approval 2001 (AVODART). What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 44 across the 27 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 27 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Prostatic Hyperplasia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 43 finished, 17 (40%) have results posted.
Among the 43 studies in Prostatic Hyperplasia by GlaxoSmithKline, this one is the 15th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2012, is one of 7 in phase 4, and was the 34th registered.
GlaxoSmithKline’s Prostatic Hyperplasia studies by the year they started, since 2003.
1 of the studies testing dutasteride in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07911501Mohamed Mahmoud DoghaPerioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation. | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing dutasteride in Prostatic Hyperplasia, from their registry updates:
Among GlaxoSmithKline’s 43 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.
-Primary objective: To assess the safety of 0.5 mg dutasteride/0.4 mg tamsulosin combination therapy for six month in BPH patients by monitoring category, frequency and severity of adverse events encountered during the treatment period.
-Secondary objective: To assess the efficacy of 0.5 mg dutasteride/0.4 mg tamsulosin combination therapy with regard to symptom improvement in BPH patients by monitoring and analyzing of changes in IPSS and Qmax after 6 months of treatment.
Visit 0 or Screening Visit (M0) - D0 + 2): Following tasks will be performed: ICF collection, subject code assignment, physical examination (vital signs, demographic data, medical history); checking of inclusion and exclusion criteria: prostate symptom score according to IPSS, laboratory tests (hematology, blood chemistry, electrolytes, total PSA level, free-to-total PSA ratio, Qmax, urinalysis, transrectal prostate ultrasonography (TRUS), 12-lead electrocardiography (ECG), scoring of Sexual Function Questionnaire (SFQ), concomitant medication assessment, IP dispensing. • Visit 1 (Month 1 (M1) - D30 ± 3): Following items will be recorded: treatment compliance, vital signs, blood chemistry, ECG, adverse events (AEs), concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. • Visit 2 (Month 2 (M2) - D60 ± 3): Following items will be recorded: treatment compliance, AEs, concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. • Visit 3 (Month 3 (M3) - D90 ± 3): Following items will be recorded: vital signs, laboratory tests (hematology, blood chemistry, electrolytes, Qmax, urinalysis, 12-lead ECG, total PSA level), concomitant medication, SFQ score, AE assessment, collecting of dispensed IP at the last visit and dispensing of new IP doses. • Visit 4 (Month 4.5 (M4) - D135 ± 3): Following items will be recorded: treatment compliance, vital signs, AEs, concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. Visit 5 (Month 6 (M6)- D180 ± 3): Following items will be recorded: treatment compliance, vital signs, prostate symptom score according to IPSS, laboratory tests (hematology, blood chemistry, electrolytes, Qmax, urinalysis, 12-lead ECG, total PSA level, free-to-total PSA ratio, TRUS; concomitant medication, SFQ score, AE assessment, collecting of the previous dispensed IPs . Follow-up Phone Call (Month 7 (M7)- D210 ± 3): To record any possible AE that may occur after discontinuation of study treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male, age ≥ 50 years. Clinical diagnosis of benign prostate hypertrophy (BPH) . International Prostate Symptom Score (IPSS) ≥ 12 Prostate volume ≥30 ml (transrectal ultrasonography). Total serum prostate specific antigen (PSA) ≥1.5 ng/mL and ≤10 ng/mL. Free-to-total PSA ratio > 20% Maximum flow rate (Qmax) >5 mL/sec and ≤15 mL/sec and post-void residual volume of \< 150 mL Willing and able to give written and comply with study procedures throughout study Able to swallow and retain oral medication Able to express personal thought and feeling Ability to read and comprehend information on the Sexual Function Inventory
Exclusion Criteria:
History or evidence of prostate cancer (e.g. positive or ultrasound, suspicious digital rectal examination).
Previous prostatic surgery (TURP, balloon dilatation, thermotherapy and stent replacement) or other invasive procedures to treat BPH.
History of flexible/rigid cystoscopy or other instrumentation of the urethra within past 7 days History of acute urine retention (AUR) within past 3 months. Any causes other than BPH result in urinary symptoms or changes in flow rate (e.g. neurogenic bladder, bladder neck contracture, urethral stricture, bladder , acute or chronic prostatitis, acute or chronic urinary tract infections).
History of breast cancer or clinical finding suggestive of malignancy. Use of any 5-alpha-reductase inhibitor (e.g. Proscar®, Propecia®), drugs with antiandrogenic properties (e.g. spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, progestational agents), drugs which induce gynecomastia or drugs which affect prostate volume, within past 6 months and throughout the study (other than as study medication). Do not use dutasteride within past 12 months. Do not use metronidazole for a long time.
Concurrent use of anabolic steroids (eg. Durabolin®). Use of phytotherapy (eg: Tadenan®, Permixon®, etc) for BPH within 2 weeks of screening visit and/or predicted to need phytotherapy during the study.
Use of any alpha-adrenoreceptor blockers (i.e. indoramin, prazosin, terazosin, tamsulosin, alfuzosin and doxazosin) within 2 weeks of screening visit and/or predicted to need any alpha blockers other than tamsulosin during the study.
Use of any alpha-adrenoreceptor agonists (e.g. pseudoephedrine, phenylephrine, ephedrine) or anticholinergics (e.g. oxybutynin, propantheline) or cholinergics (e.g. bethanecol chloride) within 48 hours prior to all uroflowmetry assessments.
to any alpha-/beta-adrenoreceptor blocker or 5-alpha-reductase inhibitor, or other chemically-related drugs.
Concurrent use of drugs known or thought to have an interaction with tamsulosin and dutasteride.
History of hepatic impairment or abnormal liver function tests at screening (defined , AST, and/or alkaline phosphatase >2 times the , or total >1.5 times the upper limit of normal).
History of renal insufficiency, or serum creatinine >1.5 times the upper limit of normal at screening.
History of malignancies other than basal cell carcinoma or squamous cell carcinoma of the skin within the past 5 years. Subjects with a prior malignancy who have had no evidence of disease for at least 5 years prior to screening are eligible.
Any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within past 6 months; medically uncontrollable diabetes or peptic ulcer disease History of postural hypotension, dizziness, vertigo or any signs and symptoms of orthostasis, which in judgments of investigator, could be exacerbated by tamsulosin History of unsuccessful treatment with tamsulosin or 'first dose' hypotensive episode on initiation of alpha-1-adrenoreceptor antagonist therapy.
History of unsuccessful treatment with finasteride or dutasteride. Willing to have a child during the treatment period or within 6 months thereafter Having female partner who is a pregnant woman or in child-bearing age and refuse to use condom for sexual protection Willing to donate blood during treatment period or within 6 months thereafter. History or current evidence of drug or alcohol abuse within past 12 months. History of any illness might confound the results of the study or poses additional risk to the patient.
Participation in or marketed drug trial within 30 days preceding the screening visit and/or during the study treatment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin
Drug: Dutasteride/Tamsulosin
Drug pages: Dutasteride · Tamsulosin
0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
Also known as: Duodart, combodart
Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.
Time frame: From start of study medication until follow-up (up to 7 months)
Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.
Time frame: From start of study medication until follow-up (up to 7 months)
Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points
A 12 lead ECG was measured at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5).
Time frame: Screening, Month 1, Month 3 and Month 6
Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
Blood samples were collected at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5) for chemistry laboratory assessments. Clinical chemistry parameters included alanine aminotrasferase (ALT), aspartate aminotrasferase (AST), creatinine, glucose, potassium, protein, sodium and urea. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for a clinical chemistry parameter are summarized.
Time frame: Screening, Month 1, Month 3 and Month 6
Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
Blood samples were collected at Screening, Month 3 (Visit 3) and Month 6 (Visit 5) for hematology laboratory assessments. Hematology parameters included basophils, leukocytes, hemoglobin (HGB), eosinophils, erythrocytes (ery), ery mean Corpuscular HGB concentration, ery mean corpuscular HGB, ery distribution width, lymphocytes, hematocrit, monocytes, neutrophils and platelets. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for hematology parameters are summarized.
Time frame: Screening, Month 3 and Month 6
Number Participants With a Negative or Positive Response at the Indicated Time Points
Urine samples were collected at Screening (SC), Month 3 (3M) and Month 6 (6M) for urinalysis laboratory assesment. Final value (FV) is defined as the latest post-Baseline value available in the study for each parameter.Urinalysis parameters included erythrocytes, glucose, ketones, leukocytes and protein. Number of participants with a negative (NEG) or positive (POS) response at the indicated time points are summarized.
Time frame: Screening, Month 3 and Month 6
Change From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points
Serum sample was collected at Baseline, Month 3 and Month 6 for assesment of total PSA. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Change from Baseline in total PSA at Month 3 and Month 6 was calculated as value at specified visist minus Baseline value.
Time frame: Baseline, Month 3 and Month 6
Free to Total PSA Ratio at the Indicated Time Points
Serum sample was collected at Screening (Baseline for participants with Free to Total PSA ratio at Month 6), and Month 6 for assessment of free to total PSA ratio. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Free to total PSA ratio at Baseline for participants with free to total PSA Ratio at Month 6 and free to total PSA ratio at month 6 are presented.
Time frame: Baseline, Month 6
Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6
The IPSS is a screening tool used to assess the symptoms of prostate related disease. The IPSS questionnaire consists of seven symptoms questions including feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 (no symptoms to almost always symptoms) for a total of maximum 35 points. IPSS total is the sum of the scores of seven questions; therefore, the possible total score ranges from 0 to 35 (0-7: Mildly symptomatic; 8-19: Moderately symptomatic; 20-35: Severely symptomatic). IPSS was assessed at Baseline and Month 6. Change from Baseline was calculated as Month 6 IPSS score- minus Baseline IPSS score.
Time frame: Baseline and Month 6
Change From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points
The Qmax is used as an indicator for the diagnosis of enlarged prostate. A lower Qmax may indicate that the enlarged prostate. Qmax was assessed at Baseline (screening), Month 3 and Month 6. Change from Baseline was calculated as Qmax score at specified timepoint minus the Baseline Qmax score.
Time frame: Baseline, Month 3 and Month 6
| Milestone | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Started | 59 |
| Completed | 52 |
| Not completed | 7 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 3 |
An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.
| Participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Any AE | 13 |
| Any SAE | 1 |
| Any treatment-related AE | 3 |
An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.
| Participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Any AE | 2 |
| Any SAE | 1 |
| Any treatment-related AE | 1 |
A 12 lead ECG was measured at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5).
| Participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Screening, n=59 | 49 |
| Month 1, n=56 | 47 |
| Month 3, n=53 | 50 |
| Month 6, n=52 | 44 |
Blood samples were collected at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5) for chemistry laboratory assessments. Clinical chemistry parameters included alanine aminotrasferase (ALT), aspartate aminotrasferase (AST), creatinine, glucose, potassium, protein, sodium and urea. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for a clinical chemistry parameter are summarized.
| Participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| ALT, n=48 | 9 |
| AST, n=49 | 6 |
| Creatinine, n=51 | 9 |
| Glucose, n=47 | 8 |
| Potassium, n=52 | 1 |
| Protein, n=56 | 4 |
| Sodium, n=53 | 0 |
| Urea, n=54 | 7 |
Blood samples were collected at Screening, Month 3 (Visit 3) and Month 6 (Visit 5) for hematology laboratory assessments. Hematology parameters included basophils, leukocytes, hemoglobin (HGB), eosinophils, erythrocytes (ery), ery mean Corpuscular HGB concentration, ery mean corpuscular HGB, ery distribution width, lymphocytes, hematocrit, monocytes, neutrophils and platelets. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for hematology parameters are summarized.
| Participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Basophils/Leukocytes, n=54 | 0 |
| Eosinophils/Leukocytes, n=46 | 5 |
| Ery Mean Corpuscular HGB Concentration, n=44 | 22 |
| Ery Mean Corpuscular Hemoglobin, n=36 | 6 |
| Ery Mean Corpuscular Volume, n=42 | 4 |
| Erythrocytes, n=49 | 3 |
| Erythrocytes Distribution Width, n=4 | 3 |
| Hematocrit, n=48 | 7 |
| Hemoglobin, n=49 | 2 |
| Leukocytes, n=47 | 7 |
| Lymphocytes/Leukocytes, n=53 | 1 |
| Monocytes/Leukocytes, n=52 | 1 |
| Neutrophils/Leukocytes, n=41 | 5 |
| Platelets, n=53 | 1 |
Urine samples were collected at Screening (SC), Month 3 (3M) and Month 6 (6M) for urinalysis laboratory assesment. Final value (FV) is defined as the latest post-Baseline value available in the study for each parameter.Urinalysis parameters included erythrocytes, glucose, ketones, leukocytes and protein. Number of participants with a negative (NEG) or positive (POS) response at the indicated time points are summarized.
| Participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Erythrocytes, SC, POS, n=59 | 4 |
| Erythrocytes, SC, NEG, n=59 | 55 |
| Erythrocytes, 3M, POS, n=54 | 6 |
| Erythrocytes, 3M, NEG, n=54 | 48 |
| Erythrocytes, 6M, POS, n=52 | 6 |
| Erythrocytes, 6M, NEG, n=52 | 46 |
| Erythrocytes, FV, POS, n=54 | 7 |
| Erythrocytes, FV, NEG, n=54 | 47 |
| Glucose, SC, POS, n=59 | 3 |
| Glucose, SC, NEG, n=59 | 56 |
| Glucose, 3M, POS, n=54 | 1 |
| Glucose, 3M, NEG, n=54 | 53 |
| Glucose, 6M, POS, n=52 | 0 |
| Glucose, 6M, NEG, n=52 | 52 |
| Glucose, FV, POS, n=54 | 0 |
| Glucose, FV, NEG, n=54 | 54 |
| Ketones, SC, POS, n=59 | 0 |
| Ketones, SC, NEG, n=59 | 59 |
| Ketones, 3M, POS, n=54 | 2 |
| Ketones, 3M, NEG, n=54 | 52 |
| Ketones, 6M, POS, n=52 | 1 |
| Ketones, 6M, NEG, n=52 | 51 |
| Ketones, FV, POS, n=54 | 1 |
| Ketones, FV, NEG, n=54 | 53 |
| Leukocytes, SC, POS, n=59 | 3 |
| Leukocytes, SC, NEG, n=59 | 56 |
| Leukocytes, 3M, POS, n=54 | 0 |
| Leukocytes, 3M, NEG, n=54 | 54 |
| Leukocytes, 6M, POS, n=52 | 6 |
| Leukocytes, 6M, NEG, n=52 | 46 |
| Leukocytes, FV, POS, n=54 | 6 |
| Leukocytes, FV, NEG, n=54 | 48 |
| Protein, SC, POS, n=59 | 9 |
| Protein, SC, NEG, n=59 | 50 |
| Protein, 3M, POS, n=54 | 6 |
| Protein, 3M, NEG, n=54 | 48 |
| Protein, 6M, POS, n=52 | 7 |
| Protein, 6M, NEG, N=52 | 45 |
| Protein, FV, POS, n=54 | 8 |
| Protein, FV, NEG, n=54 | 46 |
Serum sample was collected at Baseline, Month 3 and Month 6 for assesment of total PSA. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Change from Baseline in total PSA at Month 3 and Month 6 was calculated as value at specified visist minus Baseline value.
| Microgram per liter (ug/L) | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Month 3, n=54 | -1.499 ± 1.2263 |
| Month 6, n=52 | -1.824 ± 1.2413 |
Serum sample was collected at Screening (Baseline for participants with Free to Total PSA ratio at Month 6), and Month 6 for assessment of free to total PSA ratio. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Free to total PSA ratio at Baseline for participants with free to total PSA Ratio at Month 6 and free to total PSA ratio at month 6 are presented.
| Ratio | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Baseline, n=50 | 28.207 ± 10.5868 |
| Month 6, n=52 | 24.887 ± 8.1112 |
The IPSS is a screening tool used to assess the symptoms of prostate related disease. The IPSS questionnaire consists of seven symptoms questions including feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 (no symptoms to almost always symptoms) for a total of maximum 35 points. IPSS total is the sum of the scores of seven questions; therefore, the possible total score ranges from 0 to 35 (0-7: Mildly symptomatic; 8-19: Moderately symptomatic; 20-35: Severely symptomatic). IPSS was assessed at Baseline and Month 6. Change from Baseline was calculated as Month 6 IPSS score- minus Baseline IPSS score.
| Scores on a scale | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6 | -8.3 ± 3.92 |
The Qmax is used as an indicator for the diagnosis of enlarged prostate. A lower Qmax may indicate that the enlarged prostate. Qmax was assessed at Baseline (screening), Month 3 and Month 6. Change from Baseline was calculated as Qmax score at specified timepoint minus the Baseline Qmax score.
| Mililiter/seconds | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Month 3, n=54 | 2.77 ± 4.361 |
| Month 6, n=52 | 2.01 ± 3.684 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to Month 7).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | — | 1/59 (1.7%) | 0/59 (0%) |
| Event | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Hepatic Enzyme IncreasedInvestigations | 1/59 |
| Age, Continuous(Years) | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Mean | 66.5 ± 8.37 |
| Sex: Female, Male(Participants) | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Female | 0 |
| Male | 59 |
| Race/Ethnicity, Customized(Participants) | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg |
|---|---|
| Asian | 59 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jun 2012 to primary completion in Mar 2015, 32 months.
Results were first posted in Dec 2015, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dutasteride · Tamsulosin